Villanueva Faith, Yuan Cai, Drane Walter, Dang Long, Nguyen Thu-Cuc
Internal Medicine, University of Florida, Gainesville, USA.
Oncology, University of Florida, Gainesville, USA.
Cureus. 2020 Jan 15;12(1):e6670. doi: 10.7759/cureus.6670.
Programmed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors induce tumor response by activating the patient's own immune system to fight cancer. Tumors with high tumor mutational burden or those that express high levels of PD-1/PD-L1 are more responsive to PD1/PDL1 inhibitors. There is much interest in determining how to improve response to PD-1/PD-L1 inhibitors. We report a case of a patient with metastatic bladder cancer who was primarily resistant to treatment with PD-1/PD-L1 inhibitors, then had a complete response after developing cytomegalovirus infection.
程序性细胞死亡蛋白1（PD-1）和程序性细胞死亡配体1（PD-L1）检查点抑制剂通过激活患者自身的免疫系统来对抗癌症，从而诱导肿瘤反应。具有高肿瘤突变负荷的肿瘤或那些高表达PD-1/PD-L1的肿瘤对PD-1/PD-L1抑制剂更敏感。确定如何改善对PD-1/PD-L1抑制剂的反应备受关注。我们报告了一例转移性膀胱癌患者，该患者最初对PD-1/PD-L1抑制剂治疗耐药，而后在发生巨细胞病毒感染后出现完全缓解。
